Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
Understanding Sickle Cell Disease, Pathophysiology, and Its Treatments
Mohamad-Ali Salloum, PharmD • July 12, 2024
Share
Pathophysiology and Molecular Biology
- Hydroxyurea: This medication increases the production of fetal hemoglobin (HbF), a type of hemoglobin that does not sickle. By increasing HbF levels, hydroxyurea reduces the frequency of pain crises and the need for blood transfusions. For example, a patient taking hydroxyurea may experience fewer episodes of severe pain compared to someone not on the medication.
- Blood Transfusions: Regular blood transfusions can help reduce the risk of stroke and other complications by increasing the number of normal red blood cells in circulation. For instance, a child with a high risk of stroke may receive monthly blood transfusions to lower this risk.
- Pain Management: Pain crises are a common and debilitating symptom of SCD. Pain management strategies include over-the-counter pain relievers like ibuprofen, prescription opioids, and non-pharmacological methods such as heating pads and hydration. For example, a patient experiencing a pain crisis might use a combination of ibuprofen and a heating pad to alleviate pain.
- Bone Marrow Transplant: This is currently the only potential cure for SCD. It involves replacing the patient’s bone marrow with healthy marrow from a compatible donor. However, this procedure carries significant risks and is not suitable for all patients. For instance, a young patient with a severe form of SCD might undergo a bone marrow transplant if a suitable donor is found.
- Gene Therapy: This approach aims to correct the genetic mutation responsible for SCD. One method involves using a virus to deliver a normal copy of the HBB gene to the patient’s bone marrow cells. For example, a patient undergoing gene therapy might have their bone marrow cells modified to produce normal hemoglobin, potentially curing the disease.
- CRISPR-Cas9: This gene-editing technology can precisely target and modify specific genes. Researchers are exploring its use to correct the sickle cell mutation or to increase the production of fetal hemoglobin. For instance, a patient treated with CRISPR-Cas9 might have their genes edited to produce more HbF, reducing the severity of their symptoms.
- Voxelotor: This medication works by increasing the affinity of hemoglobin for oxygen, preventing the polymerization of HbS and the sickling of red blood cells. For example, a patient taking voxelotor might experience fewer vaso-occlusive crises compared to someone not on the medication.
- L-glutamine: This amino acid supplement has been shown to reduce the frequency of pain crises in patients with SCD. For instance, a patient taking L-glutamine might have fewer hospitalizations due to pain crises.
Comparison of Treatment Mechanisms
- Hydroxyurea: This medication increases the production of fetal hemoglobin (HbF), which does not sickle. By increasing HbF levels, hydroxyurea reduces the frequency of pain crises and the need for blood transfusions. For example, a patient taking hydroxyurea may experience fewer episodes of severe pain compared to someone not on the medication.
- Voxelotor: This medication works by increasing the affinity of hemoglobin for oxygen, preventing the polymerization of HbS and the sickling of red blood cells. For example, a patient taking voxelotor might experience fewer vaso-occlusive crises compared to someone not on the medication.
Resources:
- Mayo Clinic. Sickle cell anemia - Symptoms & causes: https://www.mayoclinic.org/diseases-conditions/sickle-cell-anemia/symptoms-causes/syc-20355876.
- Cleveland Clinic. Sickle Cell Disease (SCD): Types, Symptoms & Causes: https://my.clevelandclinic.org/health/diseases/12100-sickle-cell-disease
- Johns Hopkins Medicine. Sickle Cell Disease: https://www.hopkinsmedicine.org/health/conditions-and-diseases/sickle-cell-disease
- CDC. About Sickle Cell Disease: https://www.cdc.gov/sickle-cell/about/index.html
- NHLBI, NIH. Sickle Cell Disease - Causes and Risk Factors: https://www.nhlbi.nih.gov/health/sickle-cell-disease/causes
- Oxford Academic. Sickle-Cell Anemia Hemoglobin: The Molecular Biology of the First: https://academic.oup.com/genetics/article/167/1/1/6050610
- Blood Advances. Metabolomic and molecular insights into sickle cell disease and innovative therapies: https://ashpublications.org/bloodadvances/article/3/8/1347/260127/Metabolomic-and-molecular-insights-into-sickle
- Science News Explores. Explainer: What is sickle cell disease?: https://www.snexplores.org/article/explainer-what-is-sickle-cell-disease
- NHS. Sickle cell disease - Diagnosis: https://www.nhs.uk/conditions/sickle-cell-disease/diagnosis/
- Springer. Pathophysiology and recent therapeutic insights of sickle cell disease: https://link.springer.com/article/10.1007/s00277-020-03977-9
- Drugs.com. How does Endari work to treat sickle cell disease?: https://www.drugs.com/medical-answers/endari-work-treat-sickle-cell-disease-3323440/
List of Services
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Share
Recent articles:
References: Wood W, Quinn JM, Kashy DA. Habits in everyday life: Thought, emotion, and action. J Pers Soc Psychol . 2002;83(6):1281–1297. Wood W, Neal DT. The habitual consumer. J Consum Psychol . 2009;19(4):579–592. Neal DT, Wood W, Labrecque JS, Lally P. How do habits guide behavior? Perceived and actual triggers of habits in daily life. J Exp Soc Psychol . 2012;48(2):492–498. Wood W, Mazar A, Neal DT. Habits and goals in human behavior: Separate but interacting systems. Perspect Psychol Sci . 2021;16(1):1–16. Graybiel AM. Habits, rituals, and the evaluative brain. Annu Rev Neurosci . 2008;31:359–387. Smith KS, Graybiel AM. Habit formation. Dialogues Clin Neurosci . 2016;18(1):33–43. Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci . 2006;7(6):464–476. Graybiel AM. The basal ganglia and chunking of action repertoires. Neurobiol Learn Mem . 1998;70(1–2):119–136. Schultz W. Dopamine reward prediction error coding. Dialogues Clin Neurosci . 2016;18(1):23–32. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science . 1997;275(5306):1593–1599. Nasser HM, Calu DJ, Schoenbaum G, Sharpe MJ. The dopamine prediction error: Contributions to associative models of reward learning. Front Psychol . 2017;8:244. Kahnt T, Schoenbaum G. The curious case of dopaminergic prediction errors and learning associative information beyond value. Nat Rev Neurosci . 2025;26:169–178. Lally P, van Jaarsveld CHM, Potts HWW, Wardle J. How are habits formed: Modelling habit formation in the real world. Eur J Soc Psychol . 2010;40(6):998–1009. American Psychological Association. Harnessing the power of habits. Monitor Psychol . 2020;51(8):78–83.
References: Baddeley A. Working memory: theories, models, and controversies. Annu Rev Psychol . 2012;63:1–29. Chai WJ, Abd Hamid AI, Malin Abdullah J. Working memory from the psychological and neurosciences perspectives: a review. Front Psychol . 2018;9:401. Rogers RD, Monsell S. Costs of a predictable switch between simple cognitive tasks. J Exp Psychol Gen . 1995;124(2):207–231. Rubinstein JS, Meyer DE, Evans JE. Executive control of cognitive processes in task switching. J Exp Psychol Hum Percept Perform . 2001;27(4):763–797. Garner KG, Dux PE. Knowledge generalization and the costs of multitasking. Nat Rev Neurosci . 2023;24:98–112. Zhou X, Lei X. Wandering minds with wandering brain networks. Neurosci Bull . 2018;34(6):1017–1028. Sorella S, Crescentini C, Matiz A, et al. Resting‑state default mode network variability predicts spontaneous mind‑wandering. Front Hum Neurosci . 2025;19:1515902. Sweller J. Cognitive load during problem solving: effects on learning. Cogn Sci . 1988;12(2):257–285.
Why do we procrastinate even when tasks matter most? Discover the emotional roots of procrastination and how to stop
Confidence and self-esteem are often confused but are psychologically distinct. Learn how they differ, how each develops, and why understanding both matters for real growth.
Confidence isn’t about eliminating fear—it’s about acting despite it. Discover how courage, discomfort, and psychological growth build real confidence over time.
References: McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med . 2014;371(11):993–1004. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med . 2007;357:2109–2122. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med . 2008;358:1431–1443. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med . 2008;358:2545–2559. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med . 1991;324:781–788. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on cardiovascular and renal outcomes. N Engl J Med . 2020;383:1413–1424. Ioannidis JPA. Surrogate endpoints in clinical trials: are we being misled? BMJ . 2013;346:f314.
References: Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci . 2015;16(7):403‑18. Frisaldi E, Shaibani A, Benedetti F, Pagnini F. Placebo and nocebo effects associated with pharmacological interventions: an umbrella review. BMJ Open . 2023;13:e077243. Colloca L, Finniss D. Nocebo effects, patient‑clinician communication, and therapeutic outcomes. JAMA . 2012;307(6):567‑8. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a blinded, randomized trial of statin, placebo, and no treatment. N Engl J Med . 2021;385(23):2180‑9. Penson PE, Mancini GBJ, Toth PP, et al. Introducing the “drucebo” effect in statin therapy. J Cachexia Sarcopenia Muscle . 2018;9(6):1023‑33. Barnes K, Faasse K, Geers AL, et al. Can positive framing reduce nocebo side effects? Front Pharmacol . 2019;10:167. Caliskan EB, Bingel U, Kunkel A. Translating knowledge on placebo and nocebo effects into clinical practice. Pain Rep . 2024;9(2):e1142. von Wernsdorff M, Loef M, Tuschen‑Caffier B, Schmidt S. Effects of open‑label placebos in clinical trials: a systematic review and meta‑analysis. Sci Rep . 2021;11:3855.
References: Zaniletti I, Larson DR, Lewallen DG, Berry DJ, Maradit Kremers H. How to distinguish correlation from causation in orthopaedic research. J Arthroplasty. 2023;38(4):634–637. Rush J, Ajami M, Look KA, Margolis A. Statistics review part 10: causality and confounding. J Pharm Soc Wis. 2014;17(1):45–52. Koopmans E, Schiller C. Understanding causation in healthcare: an introduction to critical realism. Qual Health Res. 2022;32(8–9):1207–1214. Kahlert J, Gribsholt SB, Gammelager H, Dekkers OM, Luta G. Control of confounding in the analysis phase – an overview for clinicians. Clin Epidemiol. 2017;9:195–204. Shi AX, Zivich PN, Chu H. A comprehensive review and tutorial on confounding adjustment methods for estimating treatment effects using observational data. Appl Sci (Basel). 2024;14(9):3662. Gao Y, Xiang L, Yi H, Song J, Sun D, Xu B, et al. Confounder adjustment in observational studies investigating multiple risk factors: a methodological study. BMC Med. 2025;23:132. Ho FK, Brown J, Galwey NW. Regression adjustment for causal inference. BMJ Med. 2025;4:e000816. Correia LCL, Mascarenhas RF, Menezes FSC, Oliveira Junior JS, Vaccarino V, Ross JS, et al. Confounder selection in observational studies in high‑impact medical and epidemiological journals. JAMA Netw Open. 2025;8(7):e2524176.
Explore the difference between Sensitivity and Specificity
References: Zaniletti I, Larson DR, Lewallen DG, Berry DJ, Maradit Kremers H. How to Distinguish Correlation from Causation in Orthopaedic Research. J Arthroplasty. 2022;38(4):634‑637. [pmc.ncbi.nlm.nih.gov] Association of Health Care Journalists. Correlation vs. Causation. [healthjournalism.org] Rush J, Ajami M, Look K, Margolis A. Statistics Review Part 10: Causality and Confounding. J Pharm Soc Wis. [jpswi.org] Biostat Prime. Correlation vs Causation: Meaning, Differences & Examples. [biostatprime.com] Koopmans E, Schiller C. Understanding Causation in Healthcare: An Introduction to Critical Realism. Qual Health Res. 2022;32(8–9):1207–1214. [pmc.ncbi.nlm.nih.gov]